Tyson Garfield, DO
Geriatric Medicine · Aurora, CONPI 1821417395
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $382 and has fallen 77.9% since, to $84 in 2024.
Across 48 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$178
- Mylan Specialty L.p.$173
- Otsuka America Pharmaceutical, Inc.$104
- Teva Pharmaceuticals USA, Inc.$100
- Biogen$76
- Argenx US, Inc.$54
- plus $268 from 11 others
What the payments were for
- Food & beverage$953100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 6 | $178 |
| Mylan Specialty L.p. | 9 | $173 |
| Otsuka America Pharmaceutical, Inc. | 6 | $104 |
| Teva Pharmaceuticals USA, Inc. | 5 | $100 |
| Biogen | 4 | $76 |
| Argenx US, Inc. | 2 | $54 |
| Eisai Inc. | 2 | $49 |
| Avanir Pharmaceuticals, Inc. | 2 | $39 |
| GSK | 2 | $36 |
| Boehringer Ingelheim | 2 | $28 |
| Novartis | 2 | $25 |
| UCB, Inc. | 1 | $19 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Radius Health, Inc. | 1 | $13 |
| Novo Nordisk | 1 | $13 |
How this compares
$953 in reported general payments places this provider in the 85th percentile of 74 geriatric medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 110 | $74,529 |
| OzempicSemaglutide | 29 | $43,121 |
| JardianceEmpagliflozin | 38 | $35,895 |
| MyrbetriqMirabegron | 30 | $34,627 |
| TrulicityDulaglutide | 14 | $24,564 |
| XareltoRivaroxaban | 31 | $19,859 |
| LinzessLinaclotide | 23 | $19,262 |
| Spiriva RespimatTiotropium Bromide | 18 | $11,865 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $10,766 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $7,971 |
| Spiriva HandihalerTiotropium Bromide | 11 | $6,651 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $5,768 |
| Gabapentin | 137 | $3,126 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $3,101 |
| Atorvastatin Calcium | 221 | $2,965 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $28 | $47,76056 claims |
| Novo NordiskOzempic | $13 | $43,12129 claims |
| GSKTrelegy Ellipta | $36 | $10,76612 claims |
| AstraZenecaSymbicort | $16 | $5,76820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 74 geriatric medicine providers in Colorado.
Other geriatric medicine in Aurora
- Michael WassermanAurora$82K
- William HiattAurora$27K
- Herman HasselkusAurora$22K
- Jacob WalkerAurora$2K
- William ChisholmAurora$1K
- Madhu ReddyAurora$1K
- Sophie ClarkAurora$1K
- Leslie ReitmanAurora$654
- Shirley FrantzAurora$536
- Devin GilhulyAurora$408
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.